Ocugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders
December 10 2020 - 5:44PM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced that it will
postpone its 2020 Annual Meeting of Stockholders to December 23,
2020 to provide its stockholders additional time to vote on the
proposals submitted for stockholder approval at the meeting.
The record date for determining stockholders eligible to vote at
the annual meeting will remain the close of business on October 28,
2020. Stockholders who have already submitted a proxy do not need
to vote again for the reconvened annual meeting scheduled for
Wednesday, December 23, 2020 at 11 a.m. Eastern time, as the
proxies submitted will remain valid.
Ocugen stockholders as of close of business on October
28, 2020 who have not voted are encouraged to vote prior to the
Annual Meeting online at www.proxyvote.com or by telephone at
1-800-690-6903. Stockholders that need assistance voting or have
questions, may contact Ocugen’s proxy solicitation firm, Okapi
Partners, at info@okapipartners.com or (855) 208-8902.
Stockholders who have already submitted proxies and want
to change their proxy can update their vote at any time. Your
vote will be recorded at the annual meeting in accordance with your
most recently submitted proxy.
A copy of the Definitive Proxy Statement is available to
stockholders on the Company’s website and at the website maintained
by the U.S. Securities and Exchange Commission (the “SEC”) at
https://www.sec.gov.
Voting on the proposals will be open through the conclusion of
Ocugen's 2020 Annual Meeting of Stockholders on December 23,
2020 at 11:00 a.m. Eastern time. If you hold your
shares of our common stock with a broker, bank or other holder of
record as nominee or agent, you may be subject to an earlier voting
deadline and you should carefully review any materials received
from the nominee or agent regarding how to vote your shares.
Ocugen stockholders as of October 28, 2020, the record date
for the Annual Meeting, are invited to attend the virtual Annual
Meeting by visiting www.virtualshareholdermeeting.com/OCGN2020.
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate Contact:Ocugen, Inc.Sanjay
SubramanianChief Financial OfficerIR@Ocugen.com
Media Contact: LaVoieHealthScience Lisa
DeScenzaldescenza@lavoiehealthscience.com+1 978-395-5970
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024